Publication: EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
Program
Authors
Authors
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
ÖZGÜROĞLU, Mustafa
Gogishvili, M.
TÜRK, HACI MEHMET
Cicin, I.
Bentsion, D.
Gladkov, O.